-
In the next five years, Zhengzhou plans to start building 11 rail transit lines
Time of Update: 2022-11-22
In this "Zhengzhou Rail Transit 2016 Human Resource Management Consulting Project Competitive Negotiation Announcement", Zhengzhou Rail Company decided to adopt competitive negotiation method to select suppliers for 2016 human resource management consulting projects.
-
PNAS: uncovering the important role of key enzymes in cancer cell survival and metastasis
Time of Update: 2022-11-15
In summary, the results of this study suggest that SCD enzymes may act as a key regulator of cancer cell fate under metabolic stress conditions, and point out potential therapeutic strategies that target lipid balance.
-
Issue 5, 2019 - GE sells its biopharmaceutical business to Danaher Corporation
Time of Update: 2022-11-11
Recently, General Electric (GE) announced that it will sell the biopharmaceutical business of its life sciences division to Danaher for a total price of $21.
Recently, General Electric (GE) announced that it will sell the biopharmaceutical business of its life sciences division to Danaher for a total price of $21.
-
European Radiology: Prediction by CT radiomics of recurrence-free survival after gallbladder cancer
Time of Update: 2022-11-04
b Relapse-free survival differs significantly between the three risk subgroupsIn this study, the radiomic features for predicting GBC RFS were developed and extracted according to preoperative contrast-enhanced CT, and a nomogram to optimize the risk stratification and individualized risk prediction of RFS was established by combining it with pathological factors, which could realize the non-invasive early identification of high-risk GBC patients and promote the formulation of personalized treatment plans for GBC patients.
-
Youyoung, a good doctor, gave a speech on the whole process management of advanced colorectal cancer - a heavy hit in South China
Time of Update: 2022-09-09
Figure 1 Speech by the chairman of the conferenceThe first link: Academic Express - Emphasis on three-line sequence, optimizing treatment decision-makingProfessor Shi Min from Nanfang Hospital of Southern Medical University presided over the academic express session, and Professor Chen Dongliang from Sun Yat-sen University Cancer Center brought an academic sharing on the theme of "Optimization of Third-Line Chemotherapy for Advanced Colorectal Cancer" .
-
【Topics in Pediatric Anesthesia】Application of MRI Technology
Time of Update: 2022-04-30
MRI technology application The human body is very rich in water, and different tissues have different water content . MRI technology is a technology that detects the internal structure of the huma
-
With these risk factors, family members of rigid patients should be careful
Time of Update: 2022-04-27
A study from Annals of Rheumatology followed up for 35 years and analyzed HLA-B27 levels, radiographic sacroiliitis status, clinical history including chronic inflammatory back pain (CIBP), acute anterior uveitis (AAU) and many other factors to predict its value for the development of axSpA .
-
Leukemia: Oral thalidomide-cyclophosphamide-dexamethasone is an effective and safe regimen for relapsed/refractory adult Langerhans cell histiocytosis
Time of Update: 2022-04-24
A research team designed this prospective study to investigate the efficacy and safety of oral thalidomide combined with cyclophosphamide and dexamethasone (TCD) regimen in adult patients with relapsed/refractory LCH .
-
Courier comes from Omicron variant endemic areas, Johnson & Johnson announces the latest vaccine data
Time of Update: 2022-01-09
"Experimental data proves that in regions where the Omicron variant is dominant, the enhanced injection of Johnson & Johnson's new crown vaccine provides 85% of the effectiveness of preventing hospitalization .
-
Cell Metab Microbial Acetate A New Mechanism for Regulating Health and Alzheimer’s Disease Brain Immune Cell Metabolism
Time of Update: 2021-12-05
Figure 6 The number of microglia and Aβ in the brain of 5xFAD mice treated with acetate were the same as those in the SPF group (Source: Erny D et al.
-
Bring 91% of patients back to normal triglycerides and innovative oligonucleotide therapy advances to phase 3 clinical trials
Time of Update: 2021-11-14
On November 2, 2021, Ionis Pharmaceuticals announced the initiation of a pivotal Phase 3 clinical trial of the antisense oligonucleotide (ASO) therapy olezarsen under development.
Reference materials:[1] Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia.
-
Ten construction Zhejiang project steel structure construction helps improve quality and efficiency
Time of Update: 2021-10-23
Facing the high cost pressure of manual equipment on Zhoushan Island of the second phase of Zhejiang Petrochemical Project, the project department closely focused on the overall construction goals of two sets of slurry-bed residual oil hydrogenation units, according to the professional construction layout and construction of steel structures, equipment, process pipelines, etc.
-
Gene editing makes "ready-to-use" CAR-T therapy Phase 1 clinical trial results are positive
Time of Update: 2021-10-21
▲Introduction of CTX110 (picture source: CRISPR Therapeutics)In this clinical trial, a total of 26 large B-cell lymphoma patients received CTX110 treatment and were followed up for at least 28 days .
-
Ten construction company strengthens construction quality control to help project construction
Time of Update: 2021-09-13
Ten Construction Company takes the strengthening of construction quality control as a breakthrough, and through optimizing and improving the project quality management system, construction "sample guide" and other strategies, it strives to improve the construction quality of key construction projects such as the second phase of Zhejiang Petrochemical, Gulei Refining and Chemical, Shandong Weifang high-end polypropylene, etc.
-
OS is over 1.5 times, PFS has nearly doubled
Time of Update: 2021-04-24
The results of the Chinese subgroup of the CheckMate-649 study confirmed that drug O (Odivo, nivolumab) combined with chemotherapy for advanced Chinese patients achieved clinically significant overall survival (OS) and progression-free survival (PFS) ) Benefits, and a higher objective response rate (ORR), this result is consistent with the results of the overall population of advanced gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma in the study.
